Efficacy and Safety of Benralizumab, a Monoclonal Antibody against IL-5Rα, in Uncontrolled Eosinophilic Asthma.
Nonresponders to maximal guideline-based therapies of asthma account for most of the morbidity, mortality, and economic burden of the disease. Because eosinophils are key effector cells in asthmatic airway inflammation, blocking IL-5, the main cytokine responsible for its survival and activation, seems to be a rational strategy. While previous monoclonal antibodies against the IL-5 ligand resulted in inconsistent improvements in asthma outcomes, benralizumab has shown promise. Benralizumab is a monoclonal antibody against IL-5 receptor, and has an enhanced antibody dependent cell-mediated cytotoxicity function. In this article, we review the theoretical advantages of benralizumab compared to previous compounds, as well as current status of the clinical development of benralizumab in asthma. Lastly, we briefly discuss the potential role of benralizumab in chronic obstructive pulmonary disease.
a Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences , Tehran , Iran.
MirHojjat
M
Khorasanizadeh
a Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences , Tehran , Iran.
Mahsa
M
Eskian
b Division of Allergy and Immunology, Cincinnati Children's Medical Center , Cincinnati , Ohio , USA.
Amal H
AH
Assa'ad
c Department of Emergency Medicine and Division of Rheumatology, Allergy, and Immunology, Department of Medicine , Massachusetts General Hospital, Harvard Medical School , Boston , Massachusetts , USA.
Carlos A
CA
Camargo
a Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences , Tehran , Iran.|d Molecular Immunology Research Center ; and Department of Immunology, School of Medicine, Tehran University of Medical Sciences , Tehran , Iran.|e Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN) , Tehran , Iran.
Nima
N
Rezaei
D000818:Animals; D018927:Anti-Asthmatic Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000378:metabolism; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000627:therapeutic use*; D000920:Antibody-Dependent Cell Cytotoxicity; D001249:Asthma / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004351:Drug Resistance; D004804:Eosinophils / Q000276:immunology*; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D053666:Interleukin-5 Receptor alpha Subunit / Q000276:immunology
D018927:Anti-Asthmatic Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C485918:IL5RA protein, human; D053666:Interleukin-5 Receptor alpha Subunit; C571386:benralizumab
asthma; benralizumab; inflammation; interleukin-5; monoclonal antibody